Drug delivery via the pulmonary route is becoming increasingly popular, but brings a unique set of formulation challenges. In particular the small particle sizes (between 2-5 μm) required to facilitate deposition in the lung frequently mean that size-reduction steps (such as milling) are required during processing of constituents (usually the active principal) prior to formulation.